A high throughput screen for TMPRSS2 expression identifies FDA‐approved and clinically advanced compounds that can limit SARS‐CoV‐2 entry

Lear, Travis; Chen, Yanwen; Evankovich, John; Larsen, Mads; Lin, Bo; Alfaras, Irene; Kennerdell, Jason; Salminen, Laura; Camarco, Daniel; Lockwood, Karina; Tuncer, Ferhan; Liu, Jie; Myerburg, Michael; McDyer, John; Liu, Yuan; Finkel, Toren; Chen, Bill

SARS‐CoV‐2 (2019‐nCoV) is the pathogenic coronavirus responsible for the global pandemic of COVID‐19 disease. The Spike (S) protein of SARS‐CoV‐2 attaches to host lung epithelial cells through the cell surface receptor ACE2, a process dependent on host proteases including TMPRSS2. Here, we identified small molecules that can reduce surface expression of TMPRSS2 using a 2,700 FDA‐approved or current clinical trial compounds. Among these, homoharringtonine and halofuginone appear the most potent agents, reducing endogenous TMPRSS2 expression at sub‐micromolar concentrations. These effects appear to be mediated by a drug‐induced alteration in TMPRSS2 protein stability. We further demonstrate that halofuginone modulates TMPRSS2 levels through proteasomal‐mediated degradation that involves the E3 ubiquitin ligase component DDB1‐ and CUL4‐associated factor 1 (DCAF1). Finally, cells exposed to homoharringtonine and halofuginone, at concentrations of drug known to be achievable in human plasma, demonstrated marked resistance to SARS‐CoV‐2 pseudoviral infection. Given the safety and pharmacokinetic data already available for the compounds identified in our screen, these results should help expedite the rational design of human clinical trials designed to combat COVID‐19 infection.